MARKET

AXSM

AXSM

Axsome Therapeut
NASDAQ
195.09
-0.94
-0.48%
After Hours: 195.09 0 0.00% 19:30 09/25 EDT
OPEN
197.68
PREV CLOSE
196.03
HIGH
201.42
LOW
194.35
VOLUME
838.18K
TURNOVER
--
52 WEEK HIGH
260.19
52 WEEK LOW
114.91
MARKET CAP
10.22B
P/E (TTM)
-51.8939
1D
5D
1M
3M
1Y
5Y
1D
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
Benzinga · 22h ago
Axsome Therapeutics Price Target Cut to $247.00/Share From $251.00 by Morgan Stanley
Dow Jones · 1d ago
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247
Benzinga · 1d ago
Axsome Therapeutics price target lowered to $247 from $251 at Morgan Stanley
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Scholar Rock Holding (SRRK) and Vertex Pharmaceuticals (VRTX)
TipRanks · 1d ago
$100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today
Benzinga · 1d ago
Axsome Therapeutics Price Target Raised to $285.00/Share From $200.00 by Truist Securities
Dow Jones · 3d ago
Axsome Therapeutics Is Maintained at Buy by Truist Securities
Dow Jones · 3d ago
More
About AXSM
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.

Webull offers Axsome Therapeutics Inc stock information, including NASDAQ: AXSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXSM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AXSM stock methods without spending real money on the virtual paper trading platform.